Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...

aShanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai 200437, China bDepartment of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Naval Medical ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Among patients with gastrointestinal stromal tumors (GIST), the most common mesenchymal tumor of the GI tract, treatment with bezuclastinib (CGT9486) and Sutent (sunitinib) demonstrated acceptable ...

I worked closely with NCI’s Investigational Drug Branch (IDB) from 1990-2016, including as a principal investigator of one of ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

The presenting symptoms of patients with appendiceal malignant tumors. Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib ...

Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal ...

Biomarker Analysis of the Phase 3 KEYNOTE-426 Study of Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma ASCO 2024: Partitioned Overall Survival: Comprehensive Analysis of ...

Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...